ARDX
Ardelyx, Inc.
4.36
USD
This page is just a preview of the data found in TrendSpider’s full version
Ardelyx, Inc. stock is up 10.38% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 17 Oct 16:12 | 19 Jan, 2024 | 4.00 | 5598 | ||
| 18 Oct 13:39 | 19 Jan, 2024 | 4.50 | 2771 | ||
| 18 Oct 13:39 | 17 Nov, 2023 | 4.00 | 2006 | ||
| 19 Oct 13:39 | 19 Jan, 2024 | 4.00 | 6980 | ||
| 20 Oct 15:01 | 19 Jan, 2024 | 2.00 | 1959 | ||
| 24 Oct 15:43 | 19 Jan, 2024 | 1.00 | 1685 | ||
| 01 Nov 19:59 | 19 Jan, 2024 | 4.00 | 7172 | ||
| 07 Nov 14:46 | 17 Jan, 2025 | 4.50 | 243 | ||
| 14 Nov 18:09 | 19 Jan, 2024 | 5.00 | 14437 | ||
| 20 Nov 20:27 | 16 Jan, 2026 | 7.00 | 90 |
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.
